Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options
- 694 Downloads
Aromatase inhibitor induced musculoskeletal syndrome is experienced by approximately half of women taking aromatase inhibitors, impairing quality of life and leading some to discontinue treatment. Evidence for effective treatments is lacking. We aimed to understand the manifestations and impact of this syndrome in the Australian breast cancer community, and strategies used for its management.
A survey invitation was sent to 2390 members of the Breast Cancer Network Australia Review and Survey Group in April 2014. The online questionnaire included 45 questions covering demographics, aromatase inhibitor use, clinical manifestations and risk factors for the aromatase inhibitor musculoskeletal syndrome, reasons for treatment discontinuation and efficacy of interventions used.
Aromatase inhibitor induced musculoskeletal syndrome was reported by 302 (82 %) of 370 respondents. Twenty-seven percent had discontinued treatment for any reason and of these, 68 % discontinued because of the musculoskeletal syndrome. Eighty-one percent had used at least one intervention from the following three categories to manage the syndrome: doctor prescribed medications, over-the-counter/complementary medicines or alternative/non-drug therapies. Anti-inflammatories, paracetamol (acetaminophen) and yoga were most successful in relieving symptoms in each of the respective categories. Almost a third of respondents reported that one or more interventions helped prevent aromatase inhibitor discontinuation. However, approximately 20 % of respondents found no intervention effective in any category.
We conclude that aromatase inhibitor induced musculoskeletal syndrome is a significant issue for Australian women and is an important reason for treatment discontinuation. Women use a variety of interventions to manage this syndrome; however, their efficacy appears limited.
KeywordsEarly breast cancer Aromatase inhibitor Arthralgia Arthritis Myalgia Interventions
We thank the study participants, the Breast Cancer Institute of Australia (BCIA) as the fundraising arm of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG), the ANZBCTG Trial Coordination Department and the Breast Cancer Network Australia for administering the survey.
All authors have contributed to the planning and conduct of the study and the analysis of the data. All authors have approved the final submitted manuscript.
Compliance with ethical standards
Conflict of interest
No authors had any conflict of interest to declare.
This study was funded by the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).
- 1.Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486–492. doi: 10.1200/jco.2006.08.8617 CrossRefPubMedGoogle Scholar
- 2.Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570CrossRefPubMedGoogle Scholar
- 4.Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22(8):1763–1769. doi: 10.1093/annonc/mdq699 CrossRefPubMedGoogle Scholar
- 5.Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048. doi: 10.1016/s0140-6736(13)62292-8 CrossRefPubMedGoogle Scholar
- 6.Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120(1):127–134. doi: 10.1007/s10549-009-0692-7 CrossRefPubMedGoogle Scholar
- 7.Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942. doi: 10.1200/jco.2011.38.0261 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Porter D (2013) New Zealand survey of aromatase inhibitor toxicityGoogle Scholar
- 9.Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor–associated arthralgia and/or bone pain: frequency and characterization in non–clinical trial patients. Clin Breast Cancer 7(10):775–778. doi: 10.3816/CBC.2007.n.038 CrossRefPubMedGoogle Scholar
- 10.Zivian MT, Salgado B (2008) Side effects revisitied: Women’s experiences with aromatase inhibitors. Breast Cancer Action, San FranciscoGoogle Scholar
- 11.Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P (2014) A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146(1):109–116. doi: 10.1007/s10549-014-2986-7 CrossRefPubMedGoogle Scholar
- 12.Barron TI, Cahir C, Sharp L, Bennett K (2013) A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer 109(6):1513–1521. doi: 10.1038/bjc.2013.518 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Chirgwin J, Giobbie-Hurder A. Treatment adherence in the BIG 1-98 trial of tamoxifen, letrozole alone and in sequenceGoogle Scholar
- 14.Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537. doi: 10.1007/s10549-010-1132-4 CrossRefPubMedGoogle Scholar
- 18.Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE (2015) Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33(3):265–271. doi: 10.1200/jco.2014.57.6926 CrossRefPubMedGoogle Scholar
- 19.Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ (2012) Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13(4):420–432. doi: 10.1016/s1470-2045(11)70328-x CrossRefPubMedGoogle Scholar
- 21.Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31(18):2257–2264. doi: 10.1200/jco.2012.45.3068 CrossRefPubMedGoogle Scholar
- 22.Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Lang I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thurlimann B (2014) Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 143(1):159–169. doi: 10.1007/s10549-013-2792-7 CrossRefPubMedGoogle Scholar
- 23.Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor–associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28(7):1154–1160. doi: 10.1200/jco.2009.23.4708 CrossRefPubMedGoogle Scholar
- 25.Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33(10):1104–1114. doi: 10.1200/jco.2014.57.1547 CrossRefPubMedGoogle Scholar
- 26.Rastelli AL, Taylor ME, Villareal R, Jamalabadi-Majidi S, Gao F, Ellis MJ (2009) A double blind randomised placebo controlled trial of high dose vitamin D therapy on musculoskeletal pain and bone mineral density in anastrazole treated breast cancer patients with marginal vitamin D status. Paper presented at the San Antonio Breast Cancer Symposium, San AntonioGoogle Scholar
- 27.Greenlee H, Crew K, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai W, Hershman D (2013) Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer 21(4):1077–1087. doi: 10.1007/s00520-012-1628-z CrossRefPubMedGoogle Scholar
- 30.AIHW (2014) Cancer in Australia: an overview, 2014. vol Cancer series no. 90. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries, CanberraGoogle Scholar
- 31.Division PB (2011) Australian Statistics on Medicines. Commonwealth of Australia. http://www.pbs.gov.au/info/statistics/asm/asm-2011. Accessed 7 Jan 2015
- 33.Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes D, Storniolo AM, Clauw D (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372. doi: 10.1007/s10549-007-9774-6 CrossRefPubMedGoogle Scholar
- 34.Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 120(16):2403–2411. doi: 10.1002/cncr.28756 CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Henry NL, Pchejetski D, A’Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study. Br J Cancer 103(3):291–296. doi: 10.1038/sj.bjc.6605768 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P (2014) Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. Eur J Cancer 50(17):2925–2931. doi: 10.1016/j.ejca.2014.08.012 CrossRefPubMedGoogle Scholar
- 44.Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, Ellis MJ (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129(1):107–116. doi: 10.1007/s10549-011-1644-6 CrossRefPubMedGoogle Scholar
- 45.Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, Klemp JR, Fabian CJ (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111–118. doi: 10.1007/s10549-009-0495-x CrossRefPubMedGoogle Scholar
- 46.Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869–878. doi: 10.1007/s10549-010-1075-9 CrossRefPubMedGoogle Scholar
- 47.Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogues X (2013) Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 140(2):385–395. doi: 10.1007/s10549-013-2638-3 CrossRefPubMedGoogle Scholar